RAPT Therapeutics Inc. Overview

RAPT Therapeutics, Inc., a pharmaceutical company based in South San Francisco, United States, specializes in immunology, small molecule drug discovery, and computational biology services. The company focuses on developing treatments for cancer and allergic inflammatory diseases. RAPT Therapeutics operates globally and is listed on the Nasdaq stock exchange.

Recent Financial Performance

As of May 5, 2025, RAPT Therapeutics’ stock closed at $0.81. The company’s 52-week high was recorded at $4.83 on May 20, 2024, while the 52-week low was $0.75345 on April 16, 2025. The market capitalization of RAPT Therapeutics stands at $120,810,000 USD. The price-to-earnings ratio is currently -0.293584, indicating that the company is not yet profitable.

Company Focus and Services

RAPT Therapeutics is dedicated to combating cancer and allergic inflammatory diseases through its specialized services in immunology, small molecule drug discovery, and computational biology. The company’s innovative approach aims to advance therapeutic solutions in these critical areas of healthcare.

For more information about RAPT Therapeutics’ offerings and initiatives, interested parties can visit their website at www.rapt.com .